Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Ernexa Therapeutics Inc. (ERNA) had Cash Flow from Financial Activities of $9.56M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-4.02M |
|
-- |
|
-- |
|
$4.10M |
|
$-4.10M |
|
$0.10M |
|
$-4.01M |
|
$-4.01M |
|
$-4.01M |
|
$-4.01M |
|
$-4.01M |
|
$-4.01M |
|
$-4.10M |
|
$-4.06M |
|
1.18M |
|
1.18M |
|
$-3.40 |
|
$-3.40 |
|
| Balance Sheet Financials | |
$5.89M |
|
$0.08M |
|
$0.42M |
|
$6.32M |
|
$2.93M |
|
-- |
|
$0.18M |
|
$3.12M |
|
$3.20M |
|
$3.20M |
|
$3.20M |
|
1.17M |
|
| Cash Flow Statement Financials | |
$-6.42M |
|
$-0.01M |
|
|
Cash Flow from Financial Activities |
$9.56M |
$1.88M |
|
$5.03M |
|
$3.14M |
|
$0.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.42M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-125.32% |
|
-125.28% |
|
-63.48% |
|
-125.28% |
|
$2.73 |
|
$-5.43 |
|
$-5.42 |
|